New markets for Maxigesic IV
AFT Pharmaceuticals has signed an exclusive licensing agreement with Aguettant Essential Medicines to distribute Maxigesic IV in eight new European markets.
Under the deal Aguettant has rights to the medicine in Spain, Portugal, the Netherlands, Finland, Norway, Denmark, Sweden and Iceland, with sales of the medication due to commence in these territories next year.
AFT Managing Director, Dr Hartley Atkinson, said the agreement extends Maxigesic IV’s footprint across Europe, noting that in Spain alone more than 2.5 million surgeries are performed annually, while a further 1.1 million are performed in the nordic nations, with Maxigesic IV offering a non-opiate alternative for pain relief.
Source: Pharmacydaily.com.au, Friday 5 March 2021
Learn about AFT Pharmaceutical’s other Maxigesic product in the module listed below.
Related Education Modules